168 related articles for article (PubMed ID: 14978768)
1. Reducing mobilization of simian immunodeficiency virus based vectors by primer complementation.
Grunwald T; Pedersen FS; Wagner R; Uberla K
J Gene Med; 2004 Feb; 6(2):147-54. PubMed ID: 14978768
[TBL] [Abstract][Full Text] [Related]
2. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses.
Kuate S; Stefanou D; Hoffmann D; Wildner O; Uberla K
J Gene Med; 2004 Nov; 6(11):1197-205. PubMed ID: 15459964
[TBL] [Abstract][Full Text] [Related]
3. Reduced mobilization of Rev-responsive element-deficient lentiviral vectors.
Lucke S; Grunwald T; Uberla K
J Virol; 2005 Jul; 79(14):9359-62. PubMed ID: 15994835
[TBL] [Abstract][Full Text] [Related]
4. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells.
Nègre D; Mangeot PE; Duisit G; Blanchard S; Vidalain PO; Leissner P; Winter AJ; Rabourdin-Combe C; Mehtali M; Moullier P; Darlix JL; Cosset FL
Gene Ther; 2000 Oct; 7(19):1613-23. PubMed ID: 11083469
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.
Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J
Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094
[TBL] [Abstract][Full Text] [Related]
7. Transfer of primer binding site-mutated simian immunodeficiency virus vectors by genetically engineered artificial and hybrid tRNA-like primers.
Hansen AC; Grunwald T; Lund AH; Schmitz A; Duch M; Uberla K; Pedersen FS
J Virol; 2001 May; 75(10):4922-8. PubMed ID: 11312366
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel trans-lentiviral vector that affords predictable safety.
Wu X; Wakefield JK; Liu H; Xiao H; Kralovics R; Prchal JT; Kappes JC
Mol Ther; 2000 Jul; 2(1):47-55. PubMed ID: 10899827
[TBL] [Abstract][Full Text] [Related]
9. Lentiviral transduction of human hematopoietic cells by HIV-1- and SIV-based vectors containing a bicistronic cassette driven by various internal promoters.
Dupuy FP; Mouly E; Mesel-Lemoine M; Morel C; Abriol J; Cherai M; Baillou C; Nègre D; Cosset FL; Klatzmann D; Lemoine FM
J Gene Med; 2005 Sep; 7(9):1158-71. PubMed ID: 15880619
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site.
Han W; Wind-Rotolo M; Kirkman RL; Morrow CD
Virology; 2004 Dec; 330(1):221-32. PubMed ID: 15527848
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors.
Kuate S; Wagner R; Uberla K
J Gene Med; 2002; 4(4):347-55. PubMed ID: 12124977
[TBL] [Abstract][Full Text] [Related]
12. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
14. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors.
Curran MA; Kaiser SM; Achacoso PL; Nolan GP
Mol Ther; 2000 Jan; 1(1):31-8. PubMed ID: 10933909
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.
ter Brake O; Berkhout B
J Gene Med; 2007 Sep; 9(9):743-50. PubMed ID: 17628029
[TBL] [Abstract][Full Text] [Related]
16. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors.
Wagner R; Graf M; Bieler K; Wolf H; Grunwald T; Foley P; Uberla K
Hum Gene Ther; 2000 Nov; 11(17):2403-13. PubMed ID: 11096444
[TBL] [Abstract][Full Text] [Related]
17. Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain.
Liehl B; Hlavaty J; Moldzio R; Tonar Z; Unger H; Salmons B; Günzburg WH; Renner M
Gene Ther; 2007 Sep; 14(18):1330-43. PubMed ID: 17611586
[TBL] [Abstract][Full Text] [Related]
18. Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale production.
Koldej R; Cmielewski P; Stocker A; Parsons DW; Anson DS
J Gene Med; 2005 Nov; 7(11):1390-9. PubMed ID: 16025547
[TBL] [Abstract][Full Text] [Related]
19. Complementarity between 3' terminal nucleotides of tRNA and primer binding site is a major determinant for selection of the tRNA primer used for initiation of HIV-1 reverse transcription.
Yu Q; Morrow CD
Virology; 1999 Feb; 254(1):160-8. PubMed ID: 9927583
[TBL] [Abstract][Full Text] [Related]
20. Analysis of lenti- and trans-lentiviral vector genetic recombination.
Wu X; Wakefield JK; Liu H; Kappes JC
Dev Biol (Basel); 2001; 106():237-48; discussion 249, 253-63. PubMed ID: 11761237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
